Unveiling VCAM‐1’s Multifaceted Role in Secondary Diabetic Complications

Diabetes mellitus is a chronic metabolic disorder characterized by sustained hyperglycemia, tightly interlinked with a range of severe secondary complications. Diabetic retinopathy, nephropathy, and cardiomyopathy substantially contribute to the overall morbidity and mortality associated with diabetes. In light of these critical issues, it becomes imperative to unravel the intricate molecular pathways underpinning the emergence of these secondary complications. This review endeavors to furnish an all‐encompassing synopsis of ongoing research about the role of VCAM‐1 in diabetic cardiomyopathy, nephropathy, and retinopathy. It delves into the intricate molecular mechanisms that underlie VCAM‐1’s involvement, with a particular emphasis on its interactions with integrins, chemokines, and cytokines. Comprehensive literature searches were conducted across several databases, including Scopus, PubMed, and Google Scholar. To pinpoint pertinent information, specific search terms such as “Diabetes,” “diabetic retinopathy,” “diabetic nephropathy,” and “diabetic cardiomyopathy,” all‐inclusive of VCAM‐1 as a contributory factor, were employed. Epidemiological insights were gleaned from Google Scholar and the World Health Organization (WHO) website. The study topic was constructed by collating relevant data from original research publications, reviews, meta‐analyses, and cross‐referenced sources. Moreover, this review explores the therapeutic implications of targeting VCAM‐1 in the management of diabetic complications. Recent advancement in the development of VCAM‐1 inhibitors is critically evaluated. In summation, gaining a comprehensive understanding of VCAM‐1’s role in diabetic complications offers a promising avenue to mitigate their adverse impact, ultimately enhancing clinical outcomes and elevating the quality of life for individuals living with diabetes.